2-[methyl (2- { 4-[2-(thiomorpholin-4-yl)ethoxy]pyridin-2-yl } -5H,6H, 7H-cyclopenta[d]pyrimidin-4-yl)amino]-N-(propan-2-yl)acetamide | 2734204-79-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 2-[methyl (2- { 4-[2-(thiomorpholin-4-yl)ethoxy]pyridin-2-yl } -5H,6H, 7H-cyclopenta[d]pyrimidin-4-yl)amino]-N-(propan-2-yl)acetamide
• 英文别名: N-Isopropyl-2-(methyl(2-(4-(2-thiomorpholinoethoxy)pyridin-2-yl)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)amino)acetamide；2-[methyl-[2-[4-(2-thiomorpholin-4-ylethoxy)pyridin-2-yl]-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl]amino]-N-propan-2-ylacetamide
• CAS: 2734204-79-4
• 化学式: C₂₄H₃₄N₆O₂S
• 分子量: 470.639
• InChiKey: GBMIEZXDNROMQU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.42
• 重原子数：
  33.0
• 可旋转键数：
  9.0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.58
• 拓扑面积：
  83.48
• 氢给体数：
  1.0
• 氢受体数：
  8.0

文献信息

• [EN] CYCLOALKYL PYRIMIDINES AS FERROPORTIN INHIBITORS<br/>[FR] PYRIMIDINES CYCLOALKYLIQUES UTILISÉES EN TANT QU'INHIBITEURS DE LA FERROPORTINE
  申请人：GLOBAL BLOOD THERAPEUTICS INC

  公开号：WO2021222363A1

  公开（公告）日：2021-11-04

  The subject matter described herein is directed to ferroportin inhibitor compounds of Formula I or I' and pharmaceutical salts thereof, methods of preparing the compounds, pharmaceutical compositions comprising the compounds, and methods of administering the compounds for prophylaxis and/or treatment of diseases caused by a lack of hepcidin or iron metabolism disorders, particularly iron overload states, such as thalassemia, sickle cell disease and hemochromatosis, and also kidney injuries.

  本文描述的主题涉及Formula I或I'的铁蛋白抑制剂化合物及其药用盐，制备这些化合物的方法，包含这些化合物的药物组合物，以及用于预防和/或治疗由于缺乏肝铁蛋白或铁代谢紊乱引起的疾病的方法，特别是铁过载状态，如地中海贫血、镰状细胞病和血色病，以及肾脏损伤。
• [EN] METHODS OF USE FOR PYRIMIDINES AS FERROPORTIN INHIBITORS<br/>[FR] MÉTHODES D'UTILISATION DE PYRIMIDINES EN TANT QU'INHIBITEURS DE LA FERROPORTINE
  申请人：GLOBAL BLOOD THERAPEUTICS INC

  公开号：WO2021222483A1

  公开（公告）日：2021-11-04

  The subject matter described herein is directed to ferroportin inhibitor compounds of Formula (I) and pharmaceutical salts thereof, methods of preparing the compounds, pharmaceutical compositions comprising the compounds, and methods of administering the compounds for prophylaxis and/or treatment of diseases caused by a lack of hepcidin or iron metabolism disorders, particularly iron overload states, such as thalassemia, sickle cell disease and hemochromatosis, and also kidney injuries.

  本文描述的主题是针对化学式(I)的铁蛋白抑制剂化合物及其药用盐，制备这些化合物的方法，包含这些化合物的药物组合物，以及用于预防和/或治疗由于缺乏肝铁蛋白或铁代谢紊乱引起的疾病的方法，特别是铁超载状态，如地中海贫血、镰状细胞病和血色病，以及肾损伤。
• CYCLOALKYL PYRIMIDINES AS FERROPORTIN INHIBITORS
  申请人：GLOBAL BLOOD THERAPEUTICS, INC.

  公开号：US20220396562A1

  公开（公告）日：2022-12-15

  The subject matter described herein is directed to ferroportin inhibitor compounds of Formula I or I′ and pharmaceutical salts thereof, methods of preparing the compounds, pharmaceutical compositions comprising the compounds, and methods of administering the compounds for prophylaxis and/or treatment of diseases caused by a lack of hepcidin or iron metabolism disorders, particularly iron overload states, such as thalassemia, sickle cell disease and hemochromatosis, and also kidney injuries.